Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)
MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia (TRS).
Related Questions
How will the initiation of the Phase III ENIGMA‑TRS trial affect Newron’s share price in the short term?
What is the market’s perception of the potential efficacy and safety profile of evenamide for treatment‑resistant schizophrenia?
What are the projected timelines for data read‑out from the ENIGMA‑TRS trial and how might that influence valuation?
Will the trial enrollment numbers and patient selection criteria impact the likelihood of a successful outcome?
How could the results of this pivotal trial impact Newron’s future revenue forecasts and partnership opportunities?
What is the potential impact on the overall valuation of Newron if the Phase III trial meets its primary endpoints versus if it fails?
How might this news affect the trading volume and liquidity of Newron’s stock (NWRN)?
What are the regulatory implications if the trial demonstrates positive results for an FDA or EMA submission?
How does the sentiment score of 35 influence market expectations for this announcement?
How does Newron’s evenamide program compare to competing TRS therapies in terms of trial design, endpoints, and timeline?